BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TILT Biotherapeutics Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies TILT Biotherapeutics Ltd.'s drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05271318-2767@assetmemo.bio
DTSTAMP:20261121T005936Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Igrelimogene litadenorepvec: Phase 1/2 readout est. (NCT05271318)
DESCRIPTION:Igrelimogene litadenorepvec\, phase 1/2.\nStudy: Oncolytic Aden
 ovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizu
 mab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment
  for Ovarian Cancer.\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/igrelimogene-litadenorepvec#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0527131
 8
URL:https://assetmemo.bio/drug/igrelimogene-litadenorepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
